Sign In
Buy SNGX
$0.483
-0.266 (-35.48%)
At Close: Jun 03, 2026
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
07:30am, Monday, 16'th Dec 2024
FLASH 2 Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on de
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
07:30am, Monday, 02'nd Dec 2024
Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bio
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 19'th Nov 2024
Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceut
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
07:30am, Friday, 15'th Nov 2024
PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
07:15am, Thursday, 14'th Nov 2024
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
07:30am, Friday, 08'th Nov 2024
PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
07:30am, Thursday, 24'th Oct 2024
Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
07:30am, Thursday, 24'th Oct 2024
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializin
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
07:30am, Tuesday, 22'nd Oct 2024
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)
Soligenix Invited to Present at Upcoming Investor Conferences
07:30am, Wednesday, 16'th Oct 2024
PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
07:30am, Monday, 07'th Oct 2024
Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J. , Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX
Soligenix Announces Partnership with Sterling Pharma Solutions
07:30am, Thursday, 03'rd Oct 2024
U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J. , Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmace
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 20'th Sep 2024
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
07:30am, Monday, 16'th Sep 2024
PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
07:30am, Tuesday, 03'rd Sep 2024
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage b
